OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP) Files An 8-K Other Events
Item 8.01 Other Events.
OWC Pharmaceutical Research Corp. (“OWC”), represented by its wholly-owned subsidiary, One World Cannabis Ltd., a company organized and existing under the laws of Israel (“OWC-Israel”), announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel’s Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent. The allowed patent application covers the use of cannabis extracts in skin disorders, which is a key focus area for OWC’s clinical development program. OWC has performed pre-clinical studies and has completed a human safety study with a cannabis-based ointment and is in the process of procuring the necessary permits for an efficacy study on psoriatic patients.
This allowed US patent application adds significantly to OWC’s intellectual property portfolio, which includes issued patents for treatment of skin conditions in the Czech Republic and Australia, as well as other families of patent applications currently under prosecution, directed to the use of cannabis-based extracts for further clinical indications and various non-clinical applications. OWC believes that this topical ointment could offer relief for patients suffering from conditions such as Psoriatic lesions of the face, which currently lack effective alternative topical treatments.
About OWC Pharmaceutical Research Corp. (OTCMKTS:OWCP)
OWC Pharmaceutical Research Corp. is a medical cannabis research and development company. The Company is engaged in the research and development of cannabis-based medical products (the Product Prospects) for the treatment of multiple myeloma, psoriasis and fibromyalgia, as well as development of a cannabis soluble tablet delivery system that has applications for other indications. The Company also provides consulting services to governmental and private entities to assist them with developing and implementing various medical cannabis programs. As of September 30, 2016, the Company was engaged in two business activities: work with GUMI to commercialize and market the Company’s Electromagnetic Percussion Device (the Device), and research and development of Cannabis-based medical products for the treatment of a range of medical conditions and/or diseases, such as multiple myeloma, psoriasis, post-traumatic stress disorder (PTSD) migraines and a delivery system.
